Lung Cancer
High cardiorespiratory fitness may lower risk for certain cancers up to 40%
High cardiorespiratory fitness was linked to reductions in head and neck, colon, esophagus, stomach, pancreas, liver, rectum, kidney and lung cancers among men, according to a study published in the British Journal of Sports Medicine.
FDA grants regular approval to Gavreto for lung cancer subset
The FDA granted regular approval to pralsetinib for treatment of certain patients with non-small cell lung cancer.
FDA news: Prostate cancer, renal cell carcinoma therapies receive fast track designation
The FDA announced several regulatory actions the past few weeks.
Lung cancer specialist named medical oncology department chair at Temple University
Martin J. Edelman, MD, has been appointed the first chair of the department of medical oncology at Lewis Katz School of Medicine at Temple University.
Study reveals sharp decline in early-stage cancer diagnoses in first year of pandemic
The rate of new cancer diagnoses among adults declined sharply in the early days of the COVID-19 pandemic, according to study results published in The Lancet Oncology.
Highlighting the importance of screening on World Lung Cancer Day
On Aug. 1, lung and respiratory organizations come together to honor World Lung Cancer Day and raise awareness for one of the most common cancers.
World Lung Cancer Day: Advances in metastatic NSCLC; value of screening for nonsmokers
Today is World Lung Cancer Day.
Just a few minutes of vigorous physical activity a day significantly reduces cancer risk
Small amounts of vigorous intermittent lifestyle physical activity appeared associated with lower risk for cancer, according to a study published in JAMA Oncology.
VIDEO: Immunotherapy may not benefit metastatic NSCLC after 2 years with no progression
Healio spoke with Charu Aggarwal, MD, MPH, about findings from her poster presentation on the impact on duration of immunotherapy on OS in metastatic non-small cell lung cancer presented at this year’s ASCO Annual Meeting.
Combination extends PFS in lung cancer subset
The addition of amivantamab-vmjw to chemotherapy extended PFS among a subset of patients with non-small cell lung cancer, according to the agent’s manufacturer.